Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.
Archives
12/21/2011
» AMCP comments to the FDA on options for a user fee program for biosimilars and interchangeable biological products
12/21/2011
» AMCP comments to the FDA regarding the approach to address drug shortages
12/19/2011
» AMCP testimony - FDA public meeting: Biosimilar and Interchangeable Biological Product User Fee Program for fiscal years 2013-2017
12/12/2011
» AMCP comments to CMS on Proposed Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2013 and Other Proposed Changes
12/06/2011
» AMCP comments to the Food and Drug Administration (FDA) on the draft Blueprint for Prescriber Continuing Education Program for Long-acting/Extended-Release Opioid Class-wide REMS
11/22/2011
» AMCP comments Measure Applications Partnership (MAP) Performance Measurement Coordination Strategy for Post-Acute Care and Long-Term Care
11/22/2011
» AMCP comments to the Food and Drug Administration (FDA) on the draft guidance for industry on tablet scoring
11/04/2011
» AMCP comments to the Department of Health and Human Services (HHS) on the Affordable Care Act (ACA) requirement to include prescription drugs as an essential benefit.
11/03/2011
» AMCP letter to House and Senate Appropriators in support of increased FDA funding for FY12
11/01/2011
» AMCP letter to Sen. Amy Klobuchar (D-MN) in support of S 296, the "Preserving Access to Life-Saving Medications Act of 2011"
11/01/2011
» AMCP letter to Rep. Diana DeGette (D-CO) in support of HR 2245, the "Preserving Access to Life-Saving Medications Act of 2011"
10/26/2011
» AMCP summary of the Proposed Rule to the Medicare Advantage and Medicare Prescription Drug Programs for 2013: Items of Importance to Managed Care Pharmacy
10/26/2011
» AMCP comments to CMS on Improving Drug Utilization Review Controls in Part D
10/26/2011
» AMCP comments to the FDA on proposed recommendation on PDUFA for years 2013 to 2017
10/11/2011
» AMCP letter in support of HR 866, the National All Schedules Prescription Electronic Reporting Reauthorization Act
09/29/2011
» AMCP comments to CMS on the Coverage of Preventive Services Under the Patient Protection and Affordable Care Act
09/28/2011
» AMCP comments to Joint Select Committee on Deficit Reduction
09/27/2011
» AMCP comments to CMS on the Patient Protection and Affordable Care Act; Establishment of Exchanges and Quality Health Plans
09/09/2011
» AMCP comments to the Measures Application Partnership (MAP) on Safety Coordination Strategy
08/31/2011
» AMCP provides input to Patient-Centered Outcomes Research Institute (PCORI) on the working definition of "Patient-Centered Outcomes Research"
08/12/2011
» Several pharmacy and patient organizations comment to CMS on the Proposed Rule on Mental Health Centers
08/03/2011
» AMCP comments to CMS on the Proposed Rule regarding Medicare Claims Data for Performance Measurement
08/02/2011
» AMCP comments to Senate Aging Committee in response to hearing on Medicare Part D prescription drug prices
08/01/2011
» AMCP summary of the Proposed Rules Related to Reinsurance, Risk Corridors, and Risk Adjustment
08/01/2011
» AMCP summary of the Proposed Rules for State Insurance Exchanges
07/29/2011
» AMCP comments to HHS on the HIPAA Privacy Rule under Health Information Technology Economic and Clinical Health (HITECH) Act
07/26/2011
» AMCP comments to the FDA in response to a citizen's petition submitted on behalf of seven medical product manufacturers
07/25/2011
» AMCP comments to CMS on the proposed changes to the Electronic Prescribing (eRx) Incentive Program
07/13/2011
» AMCP comments to CMS on Medication Therapy Management Improvements - Standardized Format
07/12/2011
» AMCP request for immediate clarification of HCR requirements effective September 2010
07/11/2011
» AMCP comments to CMS on the alignment opportunities for Medicare and Medicaid
06/22/2011
» AMCP comments to the House Ways and Means Committee on proposed deficit reduction plan
06/22/2011
» AMCP comments to the House Energy and Commerce Committee on proposed deficit reduction plan
06/22/2011
» AMCP comments to the House Budget Committee on proposed deficit reduction plan
06/22/2011
» AMCP comments to the House Appropriations Committee on proposed deficit reduction plan
06/22/2011
» AMCP comments to Speaker Boehner on deficit reduction plan
06/22/2011
» AMCP comments to White House on deficit reduction plan
06/09/2011
» AMCP comments to FDA on User Fee Program on Biosimilars
06/07/2011
» The Health Care Reform Pharmacy Stakeholders comments to CMS on the ACO proposed rule
06/07/2011
» The Pharmacy e-Health Information Technology Collaborative comments to CMS on the ACO proposed rule
06/07/2011
» The National Transitons of Care Coalition (NTOCC) comments to CMS on the ACO proposed rule
06/07/2011
» AMCP comments to CMS on ACO Proposed Rule
05/25/2011
» AMCP Letter to House Appropriators in Support of Increased FDA Funding for FY12
05/20/2011
» AMCP Letter to Sen. Herb Kohl (D-WI) in Support of S 27, the"Access to Affordable Generics Act"
05/18/2011
» AMCP responded to a URAC call for comment on Performance Measures for Health Plan Accreditation
05/06/2011
» AMCP comments to CMS on the 2012 Call Letter requirements with regard to Part D submissions for controlled substances
05/06/2011
»AMCP Analysis of Medical-Loss-Ratio Calculations: What's In, What's Out
04/11/2011
» AMCP Letter to CMS regarding Appropriate Dispensing of Prescription Drugs in Long-Term Care Facilities
04/04/2011
» AMCP comments to CMS on the standardized format for the comprehensive medication review (CMR) action plan and summary
03/23/2011
» AMCP Letter to Congressmen on Long-Term Care Short Cycle Dispensing
03/22/2011
» AMCP comments to The National Committee for Quality Assurance (NCQA) on its 2012 Healthcare Effectiveness Data and Information Set (HEDIS) measures
03/17/2011
» AMCP Comments to House Energy & Commerce Committee on Waste, Fraud and Abuse in Medicare and Medicaid
03/17/2011
» AMCP Comments to House Ways & Means Committee on Efforts to Combat Health Care Fraud
03/17/2011
» AMCP Comments to Senate Finance Committee on Preventing Health Care Fraud
03/17/2011
» The Academy joins several organizations to send a letter to CMS on implementation of long-term care dispensing provisions
03/03/2011
» AMCP comments to the Office of the National Coordinator for HIT on the stage 2 and 3 of meaningful use of electronic health records
03/03/2011
» AMCP comments to the Centers for Medicare & Medicaid Services on the draft CY 2012 Call Letter for Medicare Advantage (MA) organizations (MAOs)
03/02/2011
» AMCP sought clarification from CMS's Center for Consumer Information and Insurance Oversight on changes that change grandfathered status
02/24/2011
» AMCP comments to the Agency for Healthcare Research and Quality on health quality measures for Medicaid-eligible adults
01/27/2011
» Letter from HHS in Response to Request for MTM Grant Funding by Sen. Barbara Mikulski
01/24/2011
» AMCP comments to the President's Council of Advisors on Science and Technology (PCAST) Report
01/11/2011
» Senate Letter of Clarification to FDA Regarding Data Exclusivity for Biosimilars
01/10/2011
» AMCP comments to the Centers for Medicare & Medicaid Services (CMS) on changes to the MA-PD contract year 2012
01/04/2011
» Letter of Support for MTM Grants from Sen. Barbara Mikulski